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Sumnuary A model system was developed to allow investigation of the frequency at which clastogenic and or
mutagenic events occur in situ in a transplantable murine fibrosarcoma tumour (MCIA-Cl) compared with in
vitro culture. The marker selected for detecting these events was the X-linked hprt (hypoxanthine-guanine
phosphonrbosyltransferase) gene. We found that the hprt gene in MCIA-Cl was not suitable for this purpose,
most likely because multiple active copies were present. To circumvent the problem, HPRT- [6-thioguanine
(6-TG)-resistant] clones were isolated by inactivating all hprt genes with methylnitrosourea. Spontaneous
revertants to hypoxanthine/aminopterin/thymidine resistance (HATR) were isolated and found to be approx-
imately 1000 times more sensitive than the parental tumour to induction of 6-TGR mutants by cobalt-60
y-rays. This sensitivity is expected for a heterozygous marker; these revertants may therefore possess only one
functional hprt locus but two or more active X chromosomes. A clone with a stable hprt gene was identified
and a neo gene was introduced. The resulting cell line (MN-i 1) could be grown as a subcutaneous tumour in
syngeneic C57BL/6 animals. The frequency of mutations arising in vivo in the marker hprt gene could be
estimated by cultunrng explanted tumour cells in the presence of 6-TG, using G418 selection to distinguish
tumour from host cells. The frequency of mutants in MN-lI cells grown as tumours was found to be 3.4-fold
higher than in tissue culture for an equivalent period of time. These data provide the first direct evidence for
the existence of mutagenic factors in a tumour environment that might contribute to tumour progression.
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It is well established that initiation and progression of cancer
is associated with multiple genomic alterations, such as
altered patterns of methylation, small-scale (intra-locus)
mutations, or large-scale (multilocus) events. Multilocus
clastogenic events such as recombinations, translocations,
inversions or deletions observed at the chromosome level are
a reflection of the increased genomic instability commonly
observed in tumours (Yunis, 1983). The cause of this
observed instability is only partially understood. Loeb (1991)
has postulated that a mutation early in the development of
cancer causes a mutator phenotype that is responsible for
subsequent instability; recent reports of such a mutator gene
in a subset of colorectal cancers support this possibility
(Leach et al., 1993; Parsons et al., 1993). Mutations in genes
affecting cell cycle check points may also predispose cells to
genomic instability (Livingstone et al., 1992; Weinert and
Lydall, 1993).
As well as these endogenous mechanisms for genomic in-
stability, we and others have postulated that exogenous fac-
tors presumed to be present in the tumour environment, such
as reactive oxygen species and nitric oxide, may contribute to
genotoxicity (Birnboim, 1983; Emerit and Cerutti, 1983;
Heppner et al., 1984; Weitzman and Weitberg, 1985; Troll
and Wiesner, 1985; Bennett et al., 1993). To test this
hypothesis, we set out to develop a tumour model system in
which loss of a marker gene (hprt) could be detected with
high sensitivity. The hprt locus is widely used for the detec-
tion of mutagenic events (intra-locus and multilocus) in
mammalian cells, including man (Vreling et al., 1985; Fuscoe
et al., 1986; K6berle and Speit, 1991; Nicklas et al., 1991;
Cole and Skopek, 1994). Most rodent studies have been
carried out using Chinese hamster cells (Stout and Caskey,
1985; Nassi-Cal6 et al., 1989; K6berle and Speit, 1991;
Schwartz et al., 1991) with relatively few studies in mouse
cells (Evans et al., 1986; Vreling et al., 1988; Morita et al.,
1991). A reported limitation to the use of the hprt locus
(which is X linked and essentially single copy) for studies of
clastogenic events is that concomitant loss of neighbouring
essential genes (multilocus lesions) will result in non-viable
mutants, i.e. lowered sensitivity for detecting induced muta-
tions. This explanation was proposed by Evans et al. (1986)
who demonstrated that the apparent rate of mutation by a
clastogenic agent (250 kVp X-rays) of a single-copy
autosomal tk gene in mouse cell lines was approximately
100-fold higher than an X-linked hprt gene.
We are unaware of any previous studies that have directly
addressed the question of mutagenic events in a transplan-
table tumour in a syngeneic animal. To establish a suitable
system, we started with a murine fibrosarcoma containing
three X chromosomes (presumably three active hprt loci).
The multiple hprt loci were inactivated by treatment with a
mutagen, following which spontaneous revertants to HAT
resistance were identified. These were screened for stable hprt
expression and tumorigenicity. Selected clones demonstrated
high sensitivity to mutation induction by ionising radiation,
indicating that a single hprt locus had reverted and that cells
were at least diploid for X-linked essential genes. The clones
were used to compare the frequency of mutational events in
cells growing as a subcutaneous tumour compared with the
same cells grown in culture.
Materais and methods
Chemicals
6-Thioguanine (6-TG), aminopterin, and N-methyl-N-
nitrosourea (MNU) were purchased from Sigma, St. Louis,
MO, USA. Geneticin (G418) was from Gibco BRL, New
York, NY, USA.
Derivation ofMCIA and sublines
MC1A fibrosarcoma was originally isolated from a male
C57BL/6 mouse that had been treated with methylcholan-
threne (Kadhim and Rees, 1984; Kadhim et al., 1987).
MClA-Cl is a variant capable of in vitro growth- that arose
spontaneously when MC1A cells were maintained in culture
for several weeks. The hprt gene(s) in MCIA-Cl cells were
inactivated by treatment with MNU (125pM) for 1 h, giving
rise to mutants resistant to 6-TG. Tumorigenicity of 18
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19956-TGI mutants was tested by sekcting for clones that most
readily formed subcutaneous tumours in syngeneic C57BL/6
female mice, 8-10 weeks of age (Charles River
Laboratories). Of those tested, MC-TGR17 was chosen. The
final step was to reactivate one of what was believed to be
two or more inactive copies of the hprt gene. Approximately
5 x 10' viable cells were cultured in HAT-medium (see
below) and 54 spontaneously arisig HAT-resistant (HATe)
clones were selected. Most exhibited a HAT, 6-TG-sensitive
(6-TGs) phenotype and were labelled as MC-TGS17-1 to
MC-TGS17-54. These clones in turn were screened to iden-
tify which exhibited most stable HPRT expression (lowest
spontaneous reversion to 6-TG-reistance); clone MC-TGS17-
51 was selce (see Results). MN-5, MN-II and MN-12 are
derivatives of MC-TGS17-51 into which a neo gene in a
retroviral vector was introduced to confer G418-resistance,
allowing tumour cells to be rdly dis l from host
cells. The vector expressng the neo gene was derived from a
retrovirus which spontaneously lost eession of a human
c-H-ras-l oncogene driven by a Mo-MuLV LTR but retained
a TNIO neomycn resistance gene driven by a SV40 early-
region promoter (Bennett et al., 1994).
Cell culture conditions andchaUlenge with inibitors
Cells were grown in Dulbecco's modified Eagle medium
(DMEM) plus 10% fetal calfserum (Gibco BRL, Burlington,
Ontario, Canada; non-selective medium) in a 5% carbon
dioxide/95% air incubator at 3TC. Plating efficiency of all
clones tested was about 50% under these conditions. HAT
medium was non-seective medium supplemented with hypox-
anthine, aminopterin and thymidine at concentrations of
I x 10-4M, 4x 10-7M, and 1.5 x 10-5M, rpeively. 6-
TG-medium was non-selective medium supplemnted with
5 x 10-5 M 6-thioguanine. Twice weely, the culture medium
was replaced with fresh non-selecfive medium containing the
appropriate drug(s). 6-TGx and HAT' colonies were scored
at either 9 days (for MN series cells) or 14 days (for MC
series cells), because of differences in the growth rates of the
two series ofcells. When cells grown in HAT medium needed
to be transferred to non-sekctive medium, they were first
cultured in HT medium (1 x 10-4M hypoxanthine and
1.5 x I0-5 M thymidine) for 2 days. G418 medium was non-
selective medium supplemented with 500 &gml1' G418.
Scoring of6-TG-resistant colonies
To measure spontaneous or induced drug-resistant colonies,
1 x 105 cells were plated per 10cm tissue culture dish. Foll-
owing incubation in 6-TG-Medium (MN series, 8-9 days;
MC series, 14 days), dishes were washed in PBS (calcium-,
magnesium-free phosphate bufferd saline), colonies fixed in
methanol for 20 min rinsed with PBS and tained with
Wright's stain for 5 min. Excess stain was renoved by gentle
washing with running water. Up to about 300 colonies (>50
cells per colony) per 10 cm dish could readily be scored under
2.5 x magnifiction. All results are expressed as mutants per
1 x 10' clonable cells, i.e. corrected for the plating efficiency,
which ranged from 40-50%.
In vitro growth rate determination
The in vitro growth rate of several MC-TGS and MN clones
was established by plating a known number of cells (1 x 101
per 6cm dish) and measuring the increase in cell number
with a Coulter Counter. Growth was followed daily for up to
7 days or until confluence. Cell doubling times were
estimated from the logarithmic phase of the growth curve.
CeU irradiation
Cells (in non-selective medium) were irradiated with cobalt-
60 ?-rays (dose rate 1.8-1.4 Gy min-'; Theratron 780,
Atomic Energy of Canada). After 7 days' expression time
with subculturing as needed, 1 x 101 viable cds (as deter-
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mined by trypan blue exclusion) were replated and chall-
enged with 6-TG medium. Unirradiated (control) cells were
treated similarly, without irradiation.
Determination ofin vivo mutationfrequency
When tumours reached approximately I cm in size (14-21
days after subcutaneous injection in 0.1 ml of PBS of 1 x 106
MC-TGS cells or 12-17 days after injection of 5 x 10' MN-
11 cells), animals were euthanise by carbon dioxide narcosis
and cervical dislocation. Tumours were removed under asep-
tic conditions and cell suspensions were prepared by
mechanical disruption. Cells were incubated for 2-4 days in
non-selctive medium to allow cell attachment and to remove
debris. Approximately 1 x 10' viable (i.e. trypan blue-
excluding) cells per 10cm dish were replated in 6-TG
medium for scoring of6-TGR mutants. Cells were also plated
in non-selective medium for determination of plating effi-
ciency. For MN-Il, the percentage of total cells which were
G418 ristant was determined by incubating a fraction of
the cells for 9 days in G418 medium; typically, 80-90% of
total cells were G418 resistant. The number of 6-TG'
mutants was corrected for platng efficiency and for G418
resistanc. All animal procedures were carried out in accor-
dance with guidelines of the Canadian Council on Animal
Care and the Animals for Research Act RSO-1990
Karyotype anaysis
Metaphase cells were prepared by addition of 0.1lIgml'
cokemid 4h before harvesL Cells were allowed to swell in
0.075 M potassium chloride for 15-20min, then fixed in
three changes of nethanol-acetic acid (3:1, v/v) and dropped
onto microscpe slides. Identification of X chromosomal
mateial in these cells was accompnished by hybridisation
with a biotinylated X chromosome-spcific composite DNA
probe (Breneman et al., 1994). Hybridisation and detection
of bound probe was accompshed with two layers of
avidin-FITC as described (Bneman et al., 1994). Represen-
tative cells were photographed with Kodak Etk-achrome 400
film on a Zeiss Axiophot photo microscope.
Rels
Karyotype analysis ofMCIA derivatives
MCIA was originarlly derived from a tumour arising in a
male mouse injected with a arcinogen, methyclholanthrene
(Kadhim and Rees, 1984; Kadhim et al., 1987). It was
anticipated that it would be aneuploid but the number of X
chromosomes was urtain Since it had proven to be rather
diffcult to obtain HPRT-(6TGR) mutants of MCIA-Cl by
MNU treatment or cobalt-60 -trays, this sug d that more
than one functional copy of the X-linked hprt gene was
present. Karyotype analysis, including the use of new X-
spcific hybridisation probes (Breneman et al., 1995), was
carried out (Table I, Figure 1). All nes were found to be
hypotetraploid with about three X chromosomes plus other
regions detected by the fluorescent probe, consistent with the
notion of multiple copies of the hprt gene in MC1A.
Establishing condtionsfor growth in 6-TG to minimise
metabolic cooperation
Mutant cells lacking hprt (normally resistant to 6-TG) can
still be kiLld by 'metabolic cooperation', i.e. passive acquisi-
tion of 6-TG nucleotide through gap junctions from neigh-
bouring cells that contain active enzyme (Trosko and Chang,
1984). A reconstruction experiment was carried out to deter-
mine the cell density at which this effect could be minimise
for our cell lines. One hundred 6-TG' MC-TGRI7 cells were
seeded onto 10cm tissue culture dishes with increasing
numbers of6-TGs MC-TGS17-51 cells. The cells were grown
in 6-TG for 14 days, following which 6-TGR colonies wereIncreased mutation frequency in atransplantable tumour
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Table I Karyotype of MCIA-Cl and its derivatives
Total number of Number ofX Number ofother
Cell line chromosomes chromosomes painted chromosomes
MClA-Cl (n = 19) 71.3 14.3 2.8 0.6 3.4 1.4
MC-TGR17 (n = 39) 65.6 ± 5.0 2.8 ± 0.6 3.2 ± 0.8
MC-TGS17-51 (n = 20) 93.5 ± 1.1** 4.7 0.9** 3.9 1.1
Results represent means ± standard deviations. The differences in number of total
chromosomes and X chromosomes are both statistically significant when MC-TGS17-51 was
compared with the other two strains (**P<0.001, ANOVA, Bonferroni post test). Otherdetails
given in Materials and methods.
Figure 1 Detection of X chromosome-specific sequences by
fluorescence in situ hybridisation in MC-TGR cells. Details as
described in Materials and methods. The large arrows locate
multiple X-chromosomes. Small arrows point to examples of
interstitial and centromeric X-specific sequences.
counted. The recovery of 6-TGR colonies was unchanged in
the presence of up to 1 x I05 6-TGs cells per 10 cm dish.
Above this cell number, there was a clear decrease in
recovery of 6-TGR colonies such that, at 1 x 106 cells, very
few colonies were recovered (data not shown). All exp-
eriments were therefore conducted at 1 x 105 cells per 10 cm
dish.
Spontaneous mutationfrequency andgrowth rates ofdifferent
HATR clones
The frequency of spontaneous mutants constitutes a back-
ground which affects the sensitivity of detection of induced
mutants. To obtain cell lines with the lowest background
possible, we screened 54 independently arising MC-TGS
(HATR, 6-TGs) clones to identify those with a low rate of
spontaneous loss of the HPRT function. These clones were
first grown in HAT medium (to eliminate any accumulated
6-TGR spontaneous mutants) and then grown in non-selective
medium for up to 28 days, following which 6-TGR colonies
were scored. Three clones were selected and analysed in
greater detail for rate of spontaneous loss ofHPRT function.
At times up to 28 days following removal of HAT, clones
were challenged with 6-TG (Figure 2a). In all cases, there
was an increase in the number of 6-TGR colonies seen as a
function of time in non-selective medium. Clone MC-TGS17-
51 appeared to be the most stable. Its spontaneous mutation
frequency was estimated to be 7.1 x l0-6± 0.2 x 10.6 per
day in one set of experiments (Figure 2a) and 8.2 x
10-6 0.8 x 106 per day in a second set of experiments
(Figure 2b). The equivalent rate for the two other clones
(17-1 and 17-25) ranged from 10 to 16 x 10-6 per day. The
growth rates of the three MC-TGS clones were not detec-
tably different from parental MClA-Cl; doubling times were
about 20 h (data not shown). Three G418-resistant subclones
derived from MC-TGS17-51, namely, MN-5, MN-l1 and
MN-12, were also tested (Figure 2b). The spontaneous muta-
tion frequency of MN-i 1 was estimated to be 5.1 x
10-6 +0.2x 10-6 per day. All three MN clones had a
significantly shorter doubling time (15-16 h) than the paren-
tal clone (data not shown). When corrected for differences in
doubling times, the rate of mutation was estimated to be
6.4 x 10-6 cells per generation for MC-TGS17-51 and
3.3 x 10-6 cells per generation for MN-lI. The average
growth rate of a pool of five spontaneously arising 6-TGR
mutant clones was not detectably different from parental
MN-Il cells, as assessed by a mixing experiment in which
6-TGR mutants were grown in the presence of MN-i 1 cells
(data not shown).
Radiation-induced 6-TGR mutants
Our objective was to develop a cell line which could detect
loss ofhprt gene function with high sensitivity, that is, have a
high ratio of induced to spontaneous mutations. We screened
three MC-TGS17 clones to assess their sensitivity to muta-
tion induction by cobalt-60 '-radiation. Within experimental
error, the number ofinduced mutations was similar (data not
shown). MC-TGS17-51 was chosen because of its stability at
the hprt locus. MC-TGS17-51, a G418' derivative (MN- l)
and parental MClA-Cl cells were compared in terms of
sensitivity to induction of 6-TGR mutants by cobalt-60 y-rays
(Figure 3). Dose-dependent increases in the number of 6-TGR
colonies were seen in the case of MC-TGS17-51 and MN-Il,
while virtually no 6-TGR colonies were observed in the
parental MClA-Cl cells. In fact, no 6-TGR colonies were
detected in three independent experiments involving a total
of 3.4 x 106 unirradiated MClA-Cl cells and 1.5 x 107
irradiated (0.5-5 Gy) cells. The proposed explanation is that
multiple functional copies of the X-linked hprt gene are
present in MClA-Cl cells (Table I and Figure 1). The
induced levels of 6-TGR colonies in MC-TGS17-51 and MN-
11 were 451 and 300 per 106 viable cells per Gy respectively.
At 5 Gy, we estimate that the induction of 6-TGR colonies in
















Figure 2 Spontaneous generation of 6-TGI mutants. (a) Three different MC-TGS clones were grown in non-selective medium for
the indicated penrods of time, then challenged with 6-TG as described in Materials and methods. Error bars represent the s.e.m. of
the average 3-9 replicate plates. (b) MN subclones, compared with MC-TGS17-51. Note difference in scale for parts (a) and (b).


















Fir%_e 3 Generation of 6-TGR mutants in MClA-Cl and
various derivatives by cobalt-60 -trays. *, MC-TGS17-51; A,
MN-ll; *, parental MCIA-Cl. Error bars represent the s.e.m.
of the average of 3-5 experiments, each involving 3-10 replicate
plates. Other details as described in Materials and methods.
MClA-Cl parental line. Sensitivity to cell killing by ionising
radiation was similar for the three lines, D3, = 3.5 Gy for
MC-TGS17-51 and MN-ll and 2.8 Gy for MClA-Cl (data
not shown).
Detection ofHPRT- mutants arising in tumowus
The primary use of the experimental model was to determine
whether the frequency of HPRT-mutants is altered as a
result of in vivo growth in subcutaneous tumours. Before
injection, three MC-TGS17 clones with different spontaneous
mutation frequencies in vitro were cultured in HAT-medium
to remove pre-existing 6-TGR mutants. Once tumours
reached about 1 cm in size, they were collected and cells were
plated in the presence of 6-TG to detect mutants that had
arisen during tumour growth. The mutation frequency of
these cells and cells grown in vitro under non-selective condi-
tions for an equivalent period of time is shown in Figure 4.
There was a trend towards higher mutation frequency in cells
derived from tumours as compared with cultured cells. Cells
derived from MC-TGS17-36 tumours had a statistically
significantly higher mutation frequency than cells from MC-
TGS17-51 tumours. To explore in more detail the relation-
ship between in vitro and in vivo mutation frequencies, MN-
11 cells, which have a low background of spontaneous muta-
tion and a selectable marker to allow distinguishing tumour
from host cells, were used (Figure 5). The mutation frequen-
cies of cells from 16 tumours (12-17 days of in vivo growth)
and 12 independent cultures were compared. The differences
in frequencies were highly significant (P<0.0001). The in
vivo frequency was 3.4 times higher than the in vitro fre-
quency. Tumour data were also examined as a function of
time to reach I cm diameter; no statistically significant differ-
ences were detected (Figure 5, inset).
Disaussion
Genomic instability is a commonly observed feature of
tumours (Nowell, 1982, 1991; Bringuier et al., 1993; Nielsen
et al., 1993). Factors intrinsic to tumour cells (such as
mutated forms of p53) may predispose these cells to further
genomic instability (Weinert and Lydall, 1993). A second
(not mutually exclusive) possibility is that instability is due to
extrinsic factors in the tumour environment, such as reactive
oxygen species or nitric oxide generated by phagocytic cells.
To explore the latter hypothesis, we have developed a new in
vitro/in vivo model system. A mouse tumour known to be
infiltrated with macrophages and granulocytes, and which is
readily transplantable in syngeneic animals, was chosen as a
starting point (Kadhim and Rees, 1984; Kadhim et al., 1987).
A tissue culture line was established from the tumour,
verified to be tumorigenic, and then genetically altered to
237
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Figre 4 Detection of 6-TGR mutants anrsing in vivo in different
MC-TGS tumours. M. The mutation frequency of cells grown
in vitro under non-selective conditions for 14-21 days before
being challenged with 6-TG. The mean ± s.e.m. of three replicate
dishes in a single experiment is shown. M. The mean mutation
frequency of cells recovered from different MC-TGS tumours.
The error bars indicate the s.e.m. of four tumours (for 17-51)
and five tumours (for 17-25 and 17-36). The tumour data were
compared by one-way ANOVA and a post Tukey-Kramer test.
which showed a statistically significant difference between 17-51
and 17-36 (P<0.01).
allow more sensitive detection of mutagenic events. We chose
the hprt gene as a surrogate for measuring cancer-related
genetic changes since loss of function of this gene can be
readily scored. A potential disadvantage of X-linked genes,
such as hprt, is that mutations resulting in multilocus dele-
tions (e.g. those caused by ionising radiation) may be non-
viable if neighbouring essential genes are also lost. This
biases the assay against such events (Evans et al., 1986;
Bradley et al., 1988; Sankaranarayanan, 1991; Schwartz et
al., 1991; Zhou et al., 1993). To overcome this problem,
many workers have introduced an exogenous marker gene
(Ashman and Davidson, 1985; Ashman, 1989; Ikehata et al.,
1989; Tindall and Stankowski, Jr. 1989; Kimura et al., 1993;
Lichtenauer-Kaligis et al., 1993). Our difficulty in obtaining
HPRT-mutants of MClA-Cl and the subsequent detection
of three copies of the X chromosome suggested a different
strategy. Since it appeared that MClA-Cl had more than
one active X chromosome and more than one active hprt
gene, we chose to create a hprt heterozygote, as has been
carried out at the tk and aprt loci (Liber and Thilly, 1982;
Sebastio et al., 1985). This was done by screening for rever-
tants to HATR. Clone MC-TGS17-51 and its derivatives were
all very similar with respect to stability of hprt (Figure 2b),
with spontaneous mutant frequencies estimated to be
<7.0 x 10-' mutants per generation, corrected for plating
efficiency. There was a very large gain in sensitivity (> 1000-
fold) for detection of radiation-induced hprt mutations, com-
pared with the parental line that is presumed to express
multiple copies of hprt. The frequency of hprt mutations
induced by cobalt-60 y-rays in the cell lines we describe
(300-450 x 10-' per Gy) is within the range of that reported
for other heterozygous marker genes (tk, aprt and gpt) in
mouse and Chinese hamster lines (Evans et al., 1986; Bradley
et al., 1988; Ikehata et al., 1989; Schwartz et al., 1991).
Figure 5 Detection of 6-TGR mutants arising in vivo in MN- II
tumours. M. The mean mutation frequency of MN-l1 cells
grown in vitro under non-selective conditions for 12- 17 days
before being challenged with 6-TG. The error bar indicates the
s.e.m. of 12 independent experiments. each involving 6-7 rep-
licate dishes of cells. . The mean mutation frequency of cells
recovered from subcutaneous tumours at 12- 17 days after
inoculation. The error bar indicates the s.e.m. of 16 separate
tumours. each analysed using six replicate dishes. Mutation fre-
quency is corrected for the percentage of cells (80-90%) which
were G418 resistant. Mutations in cultured and tumour cells were
compared by an unpaired t-test; tso-tailed P<0.0001. Inset. the
pooled tumour data in the main panel. shown bv time of in vivo
growth. The error bars indicate the s.e.m.. where the number of
tumours is indicated in parentheses. No statistically significant
differences were detected.
Our tumour model was developed to study factors in the
tumour environment that cause mutagenic or clastogenic
events. Clone MN- 1. which exhibited the lowest in vitro rate
of spontaneous gene loss, was used to test whether the in vivo
environment was 'mutagenic'. that is. whether an increase in
mutation frequency could be detected compared with in vitro
growth conditions. A highly statistically significant 3.4-fold
increase in mutant frequency was observed. It is difficult to
make precise estimates of the growth rate of cells in vivo,
since tumours contain a mixture of growing, non-growing
and dying cells. Thus, estimates of in vivo mutationfrequency
(mutants per total number of viable cells) not mutation rate
(mutants per cell generation) are presented. It is worth noting
that the doubling time of MN-l1 cells in vitro is very rapid
(16 h); hence, it is improbable that the observed increase in
mutation frequency can be explained solely by a greater
number of cell divisions in vivo compared with in vitro. A
large variance in mutant frequency among different tumours
was seen. compared with the small variance observed in
replicates of a single tumour cell suspension. This suggests a
Luria-Delbruick type of fluctuation (Kendal and Frost.
1988). To the best of our knowledge, these data are the first
to directly demonstrate that factors in the tumour environ-
ment may cause mutations at the hprt locus in a murine
syngeneic tumour model.
Most solid tumours. including human tumours. are
infiltrated with inflammatory cells, and it is well known that
a variety of inflammatory conditions such as ulcerative colitis
predispose to malignancy (Templeton. 1975: Camisa. 1984;
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Levin, 1992). While recent attention has been paid to
endogenous changes in tumour cells such as p53 and possibly
p16 mutations that can predispose cells to genomic instability
(Livingstone et al., 1992; Tlsty et al.. 1992; Kamb et al.,
1994). the new experimental system we have described will
allow us to study whether exogenous factors in the tumour
environment such as pH, oxyradicals, nitric oxide, and others
that may vary with the number of infiltrating inflammatory
cells and the necrotic state of the tumour (Yamashina et al.,
1986; Dobrowsky et al., 1991; Mareel et al., 1991; Bennett et
al., 1993; Ohshima and Bartsch. 1994; Rosin et al., 1994a,b)
are also important in genomic instability.
Abbreviations
aprt. adenine phosphonrbosyltransferase gene; gpt. bactenral xanthine
guanine phosphoribosyltransferase gene. HAT. hypoxanthine.
aminopterin and thymidine; HATR, cells resistant to HAT; hprt,
hypoxanthine-guanine phosphoribosyltransferase gene; HPRT-,
cells lacking functional hprt; neo. bacterial neomyncin gene; pgk,
phosphoglycerate kinase; 6-TG. 6-thioguanine 6-TG, cells resistant
to 6-TG: tk. thymidine kinase gene.
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